Rakuten Securities Inc. Purchases New Position in BioNTech SE (NASDAQ:BNTX)

Rakuten Securities Inc. purchased a new stake in shares of BioNTech SE (NASDAQ:BNTX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,271 shares of the company’s stock, valued at approximately $134,000.

Other hedge funds also recently bought and sold shares of the company. Eagle Bay Advisors LLC purchased a new position in BioNTech during the 2nd quarter valued at about $33,000. State of Wyoming purchased a new position in BioNTech during the 2nd quarter valued at about $26,000. Covestor Ltd purchased a new position in BioNTech during the 3rd quarter valued at about $32,000. Resurgent Financial Advisors LLC purchased a new position in BioNTech during the 4th quarter valued at about $47,000. Finally, UMB Bank n.a. purchased a new position in BioNTech during the 4th quarter valued at about $50,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. The Goldman Sachs Group reduced their price target on BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 28th. Oppenheimer started coverage on BioNTech in a report on Friday, January 5th. They set a “market perform” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $107.00 target price on shares of BioNTech in a report on Wednesday. Canaccord Genuity Group reiterated a “buy” rating and set a $171.00 target price on shares of BioNTech in a report on Thursday, March 21st. Finally, BMO Capital Markets reduced their target price on BioNTech from $127.00 to $123.00 and set an “outperform” rating on the stock in a report on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, BioNTech has an average rating of “Hold” and an average target price of $120.40.

BioNTech Stock Performance

Shares of BNTX opened at $86.40 on Thursday. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average price is $91.49 and its 200-day moving average price is $97.57. BioNTech SE has a 52 week low of $85.21 and a 52 week high of $125.83. The stock has a market cap of $20.54 billion, a P/E ratio of 20.97 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. Equities research analysts anticipate that BioNTech SE will post -1.67 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.